SentriO Oxy™ Oxygenator

The SentriO Oxy™ is an ingenious new device which enables patients breathing spontaneously and in comfort, to receive ultra-high oxygenation comparable to that from a ventilator—but without the costly drugs, barotrauma, hemodynamic disturbances and poor odds of survival. It can be used at home at a tiny fraction of current hospitalization costs or in hospitalized patients to avert ventilator dependency, cut costs and effect early recovery. The versatile, adaptable platform offers a range of dedicated purposes from protection to treatment to endurance training and prevention of high-altitude sickness.

  • Ultra-lightweight, self-fitting 24/7 Comfort-Seal mask with a smart compact manifold containing an array of specialized valves for controlling gas flow.
  • Automatically adjusting, integrated dynamic PEEP of 2-10 cm H2O
  • Easy-to-use adjustable head strap.
  • SentriO Guardian provides 99.99% viral filtration and protection.

Benign for a majority of infected, the SARS-CoV-2 virus is menacing for 20% of people who develop severe occult hypoxia associated with multi-organ failure, cytokine storm, and even rapid death. Debilitating long-term complications are increasingly recognized and affect 1/3 of those who were infected. More than 10 million Americans are at risk.

What has astounded physicians treating COVID-19 patients early on is the extremely low oxygen saturation (in the 50’s to 80’s, instead of the normal high 90’s) seen in patients without apparent respiratory distress. Such severe hypoxia (low tissue oxygen content) was previously thought to be incompatible with life.

With so little margin in oxygen reserve, patients may decompensate with any significant physiologic stress or increase in oxygen demand (such as fever)) and many suffer catastrophic damage to lungs, heart, liver, kidney, and other critical organs, along with diffuse clotting (DIC) and strokes. An autoimmune response may be triggered with severe long-term debilitation.

A prudent and urgent strategy is required to protect the vulnerable population against hypoxia-associated organ damage and avert unaffordable long-term health impairment costs, estimated at $8.5 trillion for the U.S. alone.

Historically, the treatment for respiratory failure is the ventilator. However, by the time COVID-19 patients need ventilatory support, the lung tissue is already badly damaged with diffuse edematous inflammation, making oxygen exchange and forced ventilation extremely difficult and damaging to delicate lung tissue.

COVID-19 patients’ oxygen saturation often deteriorate rapidly on the ventilator with a majority (52-85%) dying on them. New realization is to avoid intubation and keep patients from ventilators for as long as possible.

Alternatives such as CPAP, BiPAP, HFNC and ECMO all have significant drawbacks and require hospitalization at an average cost of $3,900/day for regular bed to $13,000/day for ICU bed with ventilator or $23,000/day for ICU w/ventilator + ECMO. Average cost of a COVID-19 hospitalization is $73,300, with many exceeding >$250,000.

With so little margin in oxygen reserve, patients may decompensate with any significant physiologic stress or increase in oxygen demand (such as fever) and many suffer catastrophic damage to lungs, heart, liver, and other critical organs, along with diffuse clotting (DIC) and strokes. An autoimmune response may be triggered with severe long-term debilitation.

In addition to its usefulness in oxygenating and protecting COVID patients, SentriO Oxy has many other applications including providing patients with severe end-stage cardiopulmonary diseases a higher quality of life.